UNUSUAL TOXICITY TO TRIETHYLENE MELAMINE IN A CASE OF CHRONIC MYELOGENOUS LEUKEMIA
Authors: A SLIPYAN
Journal: Annals of Internal Medicine (1953)

Case Reports1 February 1953UNUSUAL TOXICITY TO TRIETHYLENE MELAMINE IN A CASE OF CHRONIC MYELOGENOUS LEUKEMIAALVIN SLIPYAN, M.D.ALVIN SLIPYAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-38-2-331 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe search for a chemotherapeutic agent in leukemia is still in progress. This drug should have a wide margin of safety, and be very effective and easy to administer. The most recent of the drugs tried clinically is triethylene melamine.As far back as 1946, when the nitrogen mustards were introduced into medical practice for the palliative treatment of the lymphomas, leukemias, etc. by Rhodes1and a host of other investigators reporting in various journals, work had already begun to improve this form of therapy. Changing the structural formula of the mustards for new drugs was a logical sequence. Lewis...Bibliography1. Rhodes CP: Nitrogen mustard in the treatment of neoplastic disease, J. A. M. A. 131: 656 (June 22) 1946. CrossrefMedlineGoogle Scholar2. LewisCrossley MRML: Retardation of tumor growth in mice by oral administration of ethylenimine derivatives, Arch. Biochem. 26: 319 (April) 1950. MedlineGoogle Scholar3. Philips FS: Recent contributions to the pharmacology of bis (2-haloethyl) amines and sulfides, Pharmacol. Rev. 2: 281, 1950. Google Scholar4. BurchenalJohnstonCremerWebberStock JHSFMALFCC: Chemotherapy of leukemia. Effect of 2, 4, 6, triethylenimino s-triazine and related compounds on transplanted mouse leukemia, Proc. Soc. Exper. Biol. and Med. 74: 708 (Aug.) 1950. CrossrefMedlineGoogle Scholar5. RhodesKarnofskyBurchenalCraver CPDAJHLF: Triethylene melamine in the treatment of Hodgkin's disease and allied neoplasms, Tr. A. Am. Physicians 63: 136, 1950. MedlineGoogle Scholar6. BurchenalCrossleyStockRhodes JHMLCCCP: The action of certain ethylenimine (azeridine) derivatives on mouse leukemia, Arch. Biochem. 26: 321 (April) 1950. MedlineGoogle Scholar7. PhilipsThiersch FSJH: The nitrogen mustard-like actions of 2, 4, 6, tris (ethylenamino) s-triazine and other bis (ethylenimines), J. Pharmacol. and Exper. Therap. 100: 398 (Dec.) 1950. MedlineGoogle Scholar8. SilverbergDameshek JHWD: Use of triethylene melamine in treatment of leukemia and leukosarcoma, J. A. M. A. 148: 1015 (Mar.) 1952. CrossrefMedlineGoogle Scholar9. GraefKarnofskyJaegerKricheskySmith IDAVBBHW: The clinical and pathological effects of the nitrogen mustards in laboratory animals, Am. J. Path. 24: 1, 1948. MedlineGoogle Scholar10. BurchenalJohnstonStockCrossleyRhodes JHSFCCMLCP: Chemotherapy of leukemia: the effect of 2, 4, 6, triethylenimino-s-triazine, and related compounds in transplanted mouse leukemia, Proc. Soc. Exper. Biol. and Med. 74: 708-712 (Aug.) 1950, abstracted in Cancer Research 10: 208, 1950. CrossrefMedlineGoogle Scholar11. KarnofskyBurchenalArmisteadSouthamBernsteinGraverRhodes DAJHGCCMJLLFCP: Triethylene melamine in the treatment of neoplastic disease, Arch. Int. Med. 87: 477 (April) 1951. CrossrefGoogle Scholar12. WrightPrigotWrightArons JCAALTI: Further observations on the use of triethylene melamine in neoplastic diseases, Arch. Int. Med. 89: 387, 1952. CrossrefGoogle Scholar13. HansenBichel PBJ: Triethylene melamine treatment of Hodgkin's disease and other malignant diseases, Nord. Med. 47: 43-74 (Jan. 11) 1952. Google Scholar14. Rottino A: Triethylene melamine in the treatment of Hodgkin's disease and other lymphomas, New York State J. Med. 52: 346 (Feb. 1) 1952. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Elmhurst, N. Y.*Received for publication July 9, 1952.The drug was supplied by Dr. J. M. Ruegsegger, of the Lederle Laboratories Division, American Cyanamid Company. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byManagement of Reticuloendothelial MalignanciesThe clinical management of leukemiaThe Clinical Use of ChlorambucilCLINICAL EVALUATION OF CB 1348 IN LEUKEMIAS AND LYMPHOMASTriethylene Melamine in the Treatment of Lymphomas and LeukemiasClinical and hematologic effects of triethylene melamine 1 February 1953Volume 38, Issue 2Page: 331-335KeywordsChemotherapeutic agentsChronic myelogenous leukemiaDrug safetyDrugsLymphocytic leukemiaLymphomaPalliative careSafetyToxicity ePublished: 1 December 2008 Issue Published: 1 February 1953 PDF downloadLoading ...